TopiVert

TopiVert Ltd. is a clinical-stage biotechnology company headquartered in London, United Kingdom, that specializes in developing narrow spectrum kinase inhibitors for the treatment of chronic inflammatory diseases affecting the gastrointestinal tract and the eyes. Founded in 2010, TopiVert's primary focus is on creating non-systemic, locally acting medications that target conditions such as ulcerative colitis and dry eye syndrome. The company's lead program, TOP1288, is currently undergoing a Phase IIa proof of concept study for ulcerative colitis, while TOP1630, aimed at treating dry eye syndrome, is set to enter a Phase I/II study in the United States. By delivering targeted treatments at pharmacologically relevant concentrations, TopiVert aims to improve medical outcomes and enable faster commencement of effective therapies.